Lymphedema, Ovarian Cancer, Uterine Cancer, Vaginal Cancer
Conditions
Keywords
CORPUS UTERI,, ENDOMETRIUM, FALLOPIAN TUBE, OVARY, VAGINA, Lymphedema, Questionnaire, Quality of Life, 09-077, Fallopian Tubes
Brief summary
The purpose of this study is to evaluate if the Gynecologic Cancer Lymphedema Questionnaire (GCLQ) truly detects symptoms or signs of lower extremity lymphedema in patients with diagnosed lower extremity lymphedema. Lymphedema is a chronic condition in which fluid accumulates in the tissues of the body. Many cancer survivors are living with discomfort and changes in their activities due to limb swelling following cancer treatment. If the GCLQ is able to do detect signs and symptoms of lymphedema, the investigators hope to use it as a tool in the clinical care setting to help identify women at risk for or with lymphedema. In the future, this could improve clinical care through the use of a more simple and feasible way to identify lower extremity lymphedema than measuring limbs.
Interventions
BEHAVIORALlimb volume measurements and GCLQ lymphedema symptom assessment questionnaire
Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
BEHAVIORALGCLQ lymphedema symptom assessment questionnaire
The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
Sponsors
Memorial Sloan Kettering Cancer Center
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
FEMALE
Age
21 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Study group of Gynecologic cancer survivors with Lymphedema * Documented lower extremity lymphedema * History of a primary diagnosis of gynecologic cancer (vulvar, cervical and uterine only) * History of surgery for gynecologic cancer including lymph node removal * No evidence of disease or active treatment * At least 21 years of age * Able and willing to provide informed consent * English fluency Comparison Group of Gynecologic Cancer Survivors without Lymphedema * No history of lower extremity lymphedema or presence of lymphedema confirmed by limb volume measurements at the time of study participation * History of a primary diagnosis of gynecologic cancer (vulvar, cervical and uterine only) * History of surgery for gynecologic cancer including lymph node removal * No evidence of disease or active treatment * At least 21 years of age * Able and willing to provide informed consent * English fluency
Exclusion criteria
* Inability to participate in an informed consent process * Patients with a psychiatric disorder precluding response to the survey
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| To determine if the Gynecologic Cancer Lymphedema Questionnaire (GCLQ)tools detects lower extremity lymphedema symptoms in gynecologic cancer survivors & if it is a feasible assessment tool which can be used in the clinical care setting. | 2 years |
Countries
United States
Outcome results
None listed